NASDAQ:OPNT - Opiant Pharmaceuticals News Headlines

$14.35
+0.53 (+3.84 %)
(As of 09/15/2019 01:28 AM ET)
Today's Range
$13.88
Now: $14.35
$14.7762
50-Day Range
$11.60
MA: $13.73
$15.72
52-Week Range
$9.98
Now: $14.35
$23.33
Volume14,740 shs
Average Volume14,383 shs
Market Capitalization$57.97 million
P/E RatioN/A
Dividend YieldN/A
Beta0.32

Headlines

Opiant Pharmaceuticals (NASDAQ OPNT) News Headlines

Source:
DateHeadline
What You Must Know About Opiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) Beta ValueWhat You Must Know About Opiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) Beta Value
finance.yahoo.com - September 12 at 1:47 PM
Insider Selling: Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Insider Sells 10,000 Shares of StockInsider Selling: Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Insider Sells 10,000 Shares of Stock
www.americanbankingnews.com - September 5 at 6:25 PM
Zacks: Analysts Anticipate Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Will Post Quarterly Sales of $5.73 MillionZacks: Analysts Anticipate Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Will Post Quarterly Sales of $5.73 Million
www.americanbankingnews.com - August 31 at 4:07 AM
Zacks: Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Given Average Rating of "Strong Buy" by AnalystsZacks: Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - August 30 at 4:59 PM
Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Expected to Announce Earnings of $0.11 Per ShareOpiant Pharmaceuticals Inc (NASDAQ:OPNT) Expected to Announce Earnings of $0.11 Per Share
www.americanbankingnews.com - August 29 at 6:16 AM
Opiant Pharmaceuticals Announces Presentations at Two Upcoming Investor ConferencesOpiant Pharmaceuticals Announces Presentations at Two Upcoming Investor Conferences
finance.yahoo.com - August 27 at 8:01 PM
OPNT: Increased Revenue Guidance for NARCAN® Nasal Spray…OPNT: Increased Revenue Guidance for NARCAN® Nasal Spray…
finance.yahoo.com - August 13 at 11:31 PM
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2019 Results - Earnings Call TranscriptOpiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - August 10 at 10:33 AM
Edited Transcript of OPNT earnings conference call or presentation 8-Aug-19 8:30pm GMTEdited Transcript of OPNT earnings conference call or presentation 8-Aug-19 8:30pm GMT
finance.yahoo.com - August 10 at 10:33 AM
Opiant Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateOpiant Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 10:39 AM
Opiant Pharmaceuticals to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, August 8Opiant Pharmaceuticals to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, August 8
finance.yahoo.com - July 30 at 11:02 PM
Should You Worry About Opiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) CEO Salary Level?Should You Worry About Opiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) CEO Salary Level?
finance.yahoo.com - July 30 at 12:05 AM
Sanofi to make Opiant agent for cannabinoid overdoseSanofi to make Opiant agent for cannabinoid overdose
seekingalpha.com - July 24 at 10:36 AM
Opiant Pharmaceuticals Expands Partnership with Sanofi, Signs Agreement for Manufacturing OPNT004 for Treatment of Acute Cannabinoid OverdoseOpiant Pharmaceuticals Expands Partnership with Sanofi, Signs Agreement for Manufacturing OPNT004 for Treatment of Acute Cannabinoid Overdose
finance.yahoo.com - July 23 at 9:27 AM
Can We See Significant Insider Ownership On The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Share Register?Can We See Significant Insider Ownership On The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Share Register?
finance.yahoo.com - June 14 at 8:06 PM
Opiant Pharmaceuticals Inc.Opiant Pharmaceuticals Inc.
www.barrons.com - May 21 at 12:07 AM
OPNT: Encouraging Pharmacokinetic Data for OPNT003…OPNT: Encouraging Pharmacokinetic Data for OPNT003…
finance.yahoo.com - May 13 at 7:47 PM
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q1 2019 Results - Earnings Call TranscriptOpiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 8:28 AM
Edited Transcript of OPNT earnings conference call or presentation 9-May-19 8:30pm GMTEdited Transcript of OPNT earnings conference call or presentation 9-May-19 8:30pm GMT
finance.yahoo.com - May 10 at 6:46 PM
Opiant Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate UpdateOpiant Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 7:35 PM
Opiant Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, May 9Opiant Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, May 9
finance.yahoo.com - April 30 at 6:45 PM
Announcing: Opiant Pharmaceuticals (NASDAQ:OPNT) Stock Increased An Energizing 249% In The Last Five YearsAnnouncing: Opiant Pharmaceuticals (NASDAQ:OPNT) Stock Increased An Energizing 249% In The Last Five Years
finance.yahoo.com - April 28 at 5:55 PM
Pharma CEO: 'This opioid crisis has become a fentanyl crisis'Pharma CEO: 'This opioid crisis has become a fentanyl crisis'
finance.yahoo.com - April 17 at 7:19 PM
Opiant CEO, creator of Narcan, weighs in on opioid overdose crisisOpiant CEO, creator of Narcan, weighs in on opioid overdose crisis
finance.yahoo.com - April 15 at 8:17 AM
Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid OverdoseOpiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid Overdose
finance.yahoo.com - April 8 at 7:42 PM
Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting PotentialOpiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential
www.nasdaq.com - April 8 at 8:12 AM
Data published online in the Journal of Pharmacology and Experimental TherapeuticsData published online in the Journal of Pharmacology and Experimental Therapeutics
www.globenewswire.com - April 8 at 8:12 AM
Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT002, Nasal Naltrexone, for Treatment of Alcohol Use DisorderOpiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT002, Nasal Naltrexone, for Treatment of Alcohol Use Disorder
finance.yahoo.com - April 3 at 8:48 AM
Opiant Pharmaceuticals receives $3M grant for OPNT003Opiant Pharmaceuticals receives $3M grant for OPNT003
seekingalpha.com - April 1 at 7:49 PM
Opiant Pharmaceuticals Announces Award of Second Tranche of Approximately $3.0 Million from National Institutes of Health Grant for Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid OverdoseOpiant Pharmaceuticals Announces Award of Second Tranche of Approximately $3.0 Million from National Institutes of Health Grant for Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
finance.yahoo.com - April 1 at 8:38 AM
Opiant Pharmaceuticals to Present at 18th Annual Needham Healthcare ConferenceOpiant Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference
finance.yahoo.com - March 28 at 8:42 AM
OPNT: Strong Revenue Growth for NARCAN® Nasal Spray…OPNT: Strong Revenue Growth for NARCAN® Nasal Spray…
finance.yahoo.com - March 25 at 7:24 PM
Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q4 2018 Results - Earnings Call TranscriptOpiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 22 at 8:43 AM
Opiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate UpdateOpiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - March 21 at 7:38 PM
Opiant Pharmaceuticals, Inc. Estimate MomentumOpiant Pharmaceuticals, Inc. Estimate Momentum
www.nasdaq.com - March 18 at 7:49 PM
Opiant Pharmaceuticals to Report Fiscal 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 21Opiant Pharmaceuticals to Report Fiscal 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 21
finance.yahoo.com - March 18 at 7:49 PM
Adamis Pharma stock jumps after FDA agrees to review injectable opioid-overdose treatmentAdamis Pharma stock jumps after FDA agrees to review injectable opioid-overdose treatment
www.marketwatch.com - March 15 at 8:38 AM
BRIEF-Opiant Pharmaceuticals - Discontinuing Development Of OPNT001 For Treatment Of Bulimia NervosaBRIEF-Opiant Pharmaceuticals - Discontinuing Development Of OPNT001 For Treatment Of Bulimia Nervosa
www.msn.com - February 21 at 6:52 PM
Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia NervosaOpiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa
finance.yahoo.com - February 21 at 6:52 PM
Should You Take Comfort From Insider Transactions At Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)?Should You Take Comfort From Insider Transactions At Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)?
finance.yahoo.com - February 6 at 6:26 PM
OPNT: Acquires Drinabant for Acute Cannabinoid Overdose…OPNT: Acquires Drinabant for Acute Cannabinoid Overdose…
finance.yahoo.com - January 9 at 6:54 PM
Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi - NasdaqOpiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi - Nasdaq
www.nasdaq.com - December 26 at 8:32 AM
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent - GlobeNewswireOpiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent - GlobeNewswire
globenewswire.com - December 26 at 8:32 AM
Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from SanofiOpiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi
finance.yahoo.com - December 26 at 8:32 AM
Opiant Pharmaceuticals announces FDA Orange Book listing for new NARCAN nasal spray patentOpiant Pharmaceuticals announces FDA Orange Book listing for new NARCAN nasal spray patent
seekingalpha.com - December 24 at 5:12 PM
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray PatentOpiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent
finance.yahoo.com - December 24 at 8:23 AM
Adamis: An Exciting Pipeline Candidate Moves ForwardAdamis: An Exciting Pipeline Candidate Moves Forward
seekingalpha.com - December 20 at 8:29 AM
This Killer Opioid Could Become a Weapon of Mass Destruction - BloombergThis Killer Opioid Could Become a Weapon of Mass Destruction - Bloomberg
www.bloomberg.com - December 14 at 8:28 AM
Does Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) CEO Salary Reflect Performance?Does Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) CEO Salary Reflect Performance?
finance.yahoo.com - November 20 at 5:14 PM
New Research: Key Drivers of Growth for Huttig Building Products, Stratus Properties, Manitex International, Marathon Patent Group, Medallion Financial, and Opiant Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained ProductionNew Research: Key Drivers of Growth for Huttig Building Products, Stratus Properties, Manitex International, Marathon Patent Group, Medallion Financial, and Opiant Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - November 19 at 8:24 AM
This page was last updated on 9/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel